Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Glargine insulin Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Tirzepatide, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 74
States / cities: Anaheim, California • Covina, California • Greenbrae, California + 68 more

Conditions: Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions: Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss; Drug · Other
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 1 Year to 21 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Type1 Diabetes
Interventions: Glargine; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes
Interventions: LY900014, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 30
States / cities: Concord, California • Escondido, California • Fresno, California + 25 more

Conditions: DKA
Interventions: Insulin Glargine; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 2 Diabetes
Interventions: insulin lispro protamine suspension:insulin lispro rDNA origin low mix, insulin glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes, Hyperglycemia
Interventions: Insulin Glargine, Insulin, Insulin glulisine; Drug
Lead sponsor: Guillermo Umpierrez; Other
Eligibility: 60 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 2
Interventions: premeal insulin lispro mixtures, insulin glargine, metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hyperglycemia
Interventions: NPH insulin plus Complete Insulin Orders, Complete Insulin Orders; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Insulin Degludec, Insulin Glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 18
States / cities: Anaheim, California • Lomita, California • Los Angeles, California + 15 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin glargine, insulin degludec, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 18
States / cities: Inglewood, California • Los Angeles, California • Redlands, California + 14 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Glargine, LY2605541, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 47
States / cities: Concord, California • Fresno, California • La Mesa, California + 44 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine at bedtime instead of NPH, NPH twice-daily; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Exenatide (AC2993), Insulin glargine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 21
States / cities: San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 85
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Diabetes Mellitus
Interventions: Insulin Detemir, Insulin Glargine; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: AMI
Interventions: Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: IIM System, Insulin Lispro and/or Insulin Glargine; Device · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more

Conditions: Type 1 Diabetes
Interventions: glargine insulin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 19 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • Miami, Florida + 15 more

Conditions: Healthy Volunteers
Interventions: HM12460A; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Dulaglutide, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more

Search by objective public record fields.

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes

Diabetes in the Elderly: Prospective Study

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

A Study in Participants With Type I Diabetes Mellitus

Insulin Glargine Versus Twice-Daily NPH

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Molar Potency Study of HM12460A in Healthy Subjects

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)